Recordati S.p.A.

Via M. Civitali, 1,
Milan, 20148
Italy,
+39 02 487871
www.recordati.com

Recordati S.p.A. is an international pharmaceutical group dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, other Central and Eastern European countries, Turkey, North Africa, the United States of America, Canada, Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases.

M&A Summary

Buy vs Sell

Year ≤ '13 '14 '15 '16 '17 '18 T
Buy (0.4/yr) # 14 - - 2 - - 16
vol $772M $163M $935M
Sell (0.0/yr) # 2 - - - - - 2
vol $19M $19M
  18

Top M&A Advisors

Financial Deals
Join to Access.
Legal Deals
Join to Access.

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Orphan Europe SARL
$152M (2007-09-28)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest Sophartex S.A.
$19M (2004-04-27)

According to our data here at Mergr, Recordati has acquired 17 companies, including 6 in the last 5 years. A total of 4 acquisitions came from private equity firms. It has also divested 2 assets.

Recordati’s largest acquisition to date was in 2007, when it acquired Orphan Europe SARL for $152M. It’s largest disclosed sale occurred in 2004, when it sold Sophartex S.A. to SynerLab SA for $19M. Recordati has acquired in 1 US state, and 10 countries. The Company’s most targeted sectors include life science (63%) and medical products (25%).

When analyzing the medical products sector as a whole, according to Mergr, in the last 3 years, there are 335 medical products companies that have made at least 1 acquisition, 16 have acquired at least 5 companies, and 3 have acquired more than 10 companies. The most prolific strategic medical products acquirer over the past 3 years is Boston Scientific, with 13 acquisitions. The most prolific private equity acquirer in the medical products sector over the past 3 years is Apax Partners with 4 platform acquisitions.

Join Mergr and gain access to Recordati’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the medical products sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.4K Private Equity Firms
  • 119K M&A Transactions
  • 129K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 35K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.